Clinical trials: Hypertensive
Heart Failure
"ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure
This study was designed to determine if patients, who have both high blood pressure and heart failure and are currently receiving drug treatment for heart failure, have an improvement in their heart failure signs and symptoms and…
- Trial name
- NCT00219011
- Testing
- aliskiren
- Where
- 2 sites in United States, Germany
- Volunteers
- 280 people
- Sponsor
- Novartis
Hypertension
Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren
This study will compare the effects of high and low level sodium (salt) diets on blood pressure in patients with hypertension (high blood pressure) who are taking aliskiren 300 mg.
- Trial name
- NCT00441064
- Testing
- Aliskiren
- Where
- 19 sites in United States
- Volunteers
- 132 people
- Sponsor
- Novartis
Glaucoma, Ocular Hypertension
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
The main study purpose is to demonstrate the non-inferiority of T4032 compared to Lumigan® 0.01% in terms of efficacy.
- Trial name
- NCT05397600
- Testing
- Bimatoprost Ophthalmic
- Where
- 64 sites in United States, Canada and 1 more
- Volunteers
- 684 people
- Sponsor
- Laboratoires Thea
Hypertension
Irbesartan in Chinese Hypertensive Diabetics With Microalbuminuria
Primary objective: To determine if irbesartan 300mg is better than 150mg in protecting the kidneys in hypertensive patients with diabetes and microalbuminuria.
- Trial name
- NCT00334581
- Testing
- Irbesartan
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Sanofi
Hypertension
A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy
This is a prospective, observational, open-label, multi-center study, which will provide detailed information about the safety and efficacy of Twynsta tablets in Korean hypertensive patients requiring combination therapy.
- Trial name
- NCT01243268
- Testing
- Twynsta tablet
- Where
- South Korea
- Volunteers
- 674 people
- Sponsor
- Boehringer Ingelheim
Microalbuminuria, Hypertension
Management of Albuminuria in Hypertensive Diabetics
Multicenter stepped wedge cluster randomized trial of family practice clinics in Quebec and Ontario comparing the effect of introducing a Point of Care testing (POCT) for urine albumin to usual practice on quality of care in…
- Conditions
- Microalbuminuria, Hypertension, Type 2 Diabetes
- Trial name
- CLINPRADIA (NCT01907958)
- Where
- Canada
- Volunteers
- 280 people
- Sponsor
- Medpharmgene, Inc.
Hypertension
A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure
Carvedilol controlled release is a marketed drug to treat high blood pressure. This study is to compare carvedilol controlled release to carvedilol controlled release plus lisinopril (fixed-dose combination) after repeat dosing…
- Trial name
- NCT00537043
- Testing
- SK&F-105517 (COREG CR FDC)
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Hypertension
A Study to Evaluate Whether Losartan Protects the Kidney in Hypertensive Diabetic Participants With Microalbuminuria (MK0954-365 AM1)
This study will evaluate whether losartan protects the kidney in hypertensive Type II diabetic participants with microalbuminuria.
- Trial name
- NCT01390415
- Volunteers
- 136 people
- Sponsor
- Organon and Co
Uncomplicated Hypertension, Hypertension
The Efficacy And Safety Of Lacidipine And Amlodipine Once-Daily Treatment In Hypertensive Adult Patients
The sustained reduction in elevated blood pressure and lower incidence of adverse events of Lacidipine may provide additional benefits for hypertension patients than other CCBs (calcium channel blockers).
- Conditions
- Uncomplicated Hypertension, Hypertension, Essential
- Trial name
- NCT00338338
- Testing
- Lacidipine 4 or 6 mg (oral), Amlodipine 5 or 10 mg(oral)
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline